ArticleVeterinary world2025
Development of a cost-effective serodiagnosis for African swine fever using solubility-enhanced recombinant p54, p30, and p72.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and Evaluation of Three Indirect ELISA Methods Based on Novel Recombinant ASFV Antigens for Serological Detection of African Swine Fever.Pathogens (Basel, Switzerland) · 2026Article
- Novel B cell epitopes mapping in pD205R protein of African swine fever virus using monoclonal antibodies.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The rapid spread of African swine fever (ASF) in Indonesia and other Asian countries has devastated domestic and wild pig populations. In the absence of a viable vaccine, ASF control depends on strict biosecurity measures and the prompt culling of infected animals. Accurate and timely detection is therefore essential to limit disease transmission, highlighting the urgent need for reliable diagnostic tools. This study aimed to develop serological assays for ASF virus (ASFV) antibody detection using recombinant ASFV proteins. Materials and Methods: Three key ASFV structural proteins-p30, p54, and p72-were heterologously expressed in Results: The solubility-optimized p54 antigen was successfully used to develop an indirect ELISA, while the insoluble p30 retained sufficient antigenicity for immunoblot-based detection. The p54-based ELISA showed high diagnostic performance, achieving an area under the curve of 0.936, with 91% sensitivity and 85% specificity. Agreement with a commercial ELISA kit was substantial (Cohen's kappa = 0.635). Immunoblotting confirmed that all recombinant proteins maintained strong antigenicity and diagnostic specificity. Conclusion: Recombinant ASFV proteins p54 and p30 demonstrated strong potential for serological diagnostics when expressed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.